Dr. Heinzerling on Remaining Challenges for Treating NSCLC

Josh H. Heinzerling, MD
Published: Friday, Nov 17, 2017



Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses remaining challenges for treating stage III non–small cell lung cancer (NSCLC).

Improving efficacy and outcomes for patients with stage III NSCLC is a priority, followed by reducing toxicity.

When chemotherapy is combined with radiation therapy, overall survival, efficacy, and radiation increase. Adding immunotherapy rather than cytotoxic chemotherapy and a change in treatment strategies may help to increase efficacy while decreasing toxicity, explains Heinzerling.


Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses remaining challenges for treating stage III non–small cell lung cancer (NSCLC).

Improving efficacy and outcomes for patients with stage III NSCLC is a priority, followed by reducing toxicity.

When chemotherapy is combined with radiation therapy, overall survival, efficacy, and radiation increase. Adding immunotherapy rather than cytotoxic chemotherapy and a change in treatment strategies may help to increase efficacy while decreasing toxicity, explains Heinzerling.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x